E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy
Status:
Active, not recruiting
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is testing the use E-B-FAHF-2 Chinese herbal therapy in combination
with multi-food oral immunotherapy (OIT) and Xolair® (Omalizumab) to help children and adults
who are allergic to foods be able to safely tolerate food allergens. Specifically in this
protocol, the food allergens are milk, egg, peanut, almond, cashew, hazelnut, walnut, sesame,
and/or wheat. Omalizumab is considered an investigational drug for the treatment of food
allergies in children and adults. Investigational means it has not been approved by the Food
and Drug Administration (FDA) for use in the U.S. The researchers hope to learn whether the
addition of Chinese herbal therapy (E-B-FAHF-2) can improve the outcome of sustained
unresponsiveness (which is the ability to consume a food allergen and pass an oral food
challenge after being off treatment for 3 months) as compared to placebo (i.e. subjects with
OIT/Omalizumab + herbal vs. OIT/Omalizumab + placebo), and will help adults and children be
able to safely ingest the foods they are allergic to.